Prelude Therapeutics priced an underwritten equity offering of 18,018,014 shares of its common stock at $4.44 per share, generating approximately $90 million in gross proceeds. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions.
The offering also included pre‑funded warrants that allow holders to purchase up to 2,252,252 shares at $4.4399 per warrant. The company plans to use the net proceeds primarily for general corporate purposes, with a focus on funding research, preclinical and clinical development of its product candidates, and increasing working capital and capital expenditures.
Prelude Therapeutics is a clinical‑stage precision oncology company whose pipeline features KAT6A degraders, JAK2V617F mutant selective inhibitors, and the breast‑cancer candidate PRT13722. The capital raise provides essential liquidity to advance these programs, especially after the company reported rapid cash burn of $56 million over the last twelve months and more cash than debt on its balance sheet.
Management’s decision to raise capital demonstrates confidence in the pipeline and the ability to secure funding. The company’s recent presentation of complete‑tumor‑regression data for PRT13722 at the AACR 2026 meeting underscores the progress that the new funds will support.
The equity offering is a significant financing event that will enable Prelude to sustain its R&D momentum and maintain its competitive position in the oncology landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.